摘要
随着人们对肿瘤免疫治疗的不断研究和越来越深入的认识,肿瘤疫苗也在这百年间取得了巨大的进步。然而,包括肿瘤疫苗在内的大多数新一代疫苗都是免疫原性较差的亚单位疫苗,因此在其制剂中基本上都需要免疫佐剂来补偿免疫抑制。目前免疫佐剂作为一种与疫苗抗原联合给药时能够增强疫苗免疫反应的强度、广度和持久性的免疫调节剂,被广泛用于疫苗开发,是大部分疫苗产品不可缺少的组成部分。该文首先介绍当前肿瘤疫苗现状,然后就目前可用于肿瘤疫苗的经典及新型免疫佐剂及其应用进展进行了简要的归纳,最后从免疫佐剂的作用机制、特性、免疫有效性、耐药性等方面总结了肿瘤疫苗所面临的挑战与对策,以期达到肿瘤疫苗研发匹配和设计最佳免疫佐剂的作用。
With the continuous research and more in-depth understanding of tumor immunotherapy,tumor vaccines have also experienced great progress in the past 100 years.However,most of the new generation vaccines,including tumor vaccines,are subunit vaccines with poor immunogenicity and essentially require immune adjuvants in their formulations to compensate for immunosuppression.Currently,immune adjuvamts,which can enhance the intensity,breadth and persistence of vaccine immune response when administered in combination with vaccine antigens,are widely used in vaccine development and are an indispensable part of most vaccine products.This paper firstly introduces the current status of tumor vaccines,then briefly summarizes the classical and novel immune adjuvants currently available for tumor vaccines and their application progress,and finally summarizes the challenges and countermeasures faced by tumor vaccines from the aspects of the mechanism of action,characteristics,immune effectiveness and drug resistance of immune adjuvants,in order to achieve the role of matching and designing the best immune adjuvant for tumor vaccine development.
作者
薛雅
戚缘
朱文宇
蒋华
XUE Ya;QI Yuan;ZHU Wenyu;JIANG Hua(Department of Oncology,Changzhou Second People's Hospital,Nanjing Medical University,Jiangsu Changzhou 213164,China)
出处
《现代肿瘤医学》
2025年第10期1822-1830,共9页
Journal of Modern Oncology
基金
南京医科大学常州医学中心临床研究项目(编号:CMCC202201)。
关键词
肿瘤
免疫佐剂
肿瘤疫苗
免疫治疗
tumor
immune adjuvant
tumor vaccine
immunotherapy
